期刊文献+

尼洛替尼的合成 被引量:4

Synthesis of Nilotinib
原文传递
导出
摘要 以3-氨基-4-甲基苯甲酸甲酯(2)为原料,采用一锅法,首先与氰胺发生反应,再与(E)-3-二甲胺基-1-(3-吡啶基)-2-丙烯-1-酮(5)环合,再经皂化,得到关键中间体4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯甲酸(7),7经酰氯化后与3-(4-甲基-1H-咪唑基)-5-三氟甲基苯胺(10)缩合得到尼洛替尼,总收率32%(以2计)。 4-Methyl-3- [ (4-pyridin-3-yl-pyrimidin-2-yl) amino~ benzoic acid (7) was obtained in one-pot process, by the reaction of methyl 3-amino-4-methylbenzoate (2) with cyanamide followed by cyclization with (E) -3- dimethylamino-l-pyridin-3-yl-propenone (5), and then hydrolysis. Finally nilotinib was synthesized by acyl-chloration of 7 and condensation with 3- (4-methyl-lH-imidazol-l-yl) -5- (trifluoromethyl) aniline (10) with an overall yield of 32 % based on 2.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第9期801-804,共4页 Chinese Journal of Pharmaceuticals
关键词 尼洛替尼 抗肿瘤药 合成 nilotinib antimmor synthesis
  • 相关文献

参考文献9

  • 1杨千姣,赵临襄.尼洛替尼[J].中国药物化学杂志,2008,18(2):159-160. 被引量:1
  • 2Breitenstein W,Furet P,Jacob S,et al.Inhibitors of tyrosine kinases:WO,2004005281[P].2004-01-15. 被引量:1
  • 3Ueda S,Su M,Buchwald SL,et al.Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles:application to the synthesis of nilotinib[J].JAm Chem Soc,2012,134 (1):700-706. 被引量:1
  • 4Wang YL,Li J,Kansal VK,et al.Nilotinib intermediates and preparation thereof:WO,2010009402[P].2010-01-21. 被引量:1
  • 5Yeori A,Wang YL,Li J,et al.Preparation of nilotinib and intermediates thereof:WO,2010060074[P].2010-05-27. 被引量:1
  • 6Huang WS,Shakespeare WC.An efficient synthesis of nilotinib (AMN107)[J].Synthesis,2007,2007 (14):2121-2124. 被引量:1
  • 7Deadman B J,Hopkin MD,Ley SV,et al.The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib,nilotinib and dasatinib[J].Org Biomol Chem,2013,11 (11):1766-1780. 被引量:1
  • 8陈永江,王丽华,周红,王从站.尼罗替尼的合成[J].中国医药工业杂志,2009,40(6):401-403. 被引量:7
  • 9禹艳坤,王超,刘爱霞,冀亚飞.尼洛替尼的合成研究[J].化学试剂,2011,33(3):266-268. 被引量:5

二级参考文献19

  • 1杨建良.尼洛替尼:一种新的抗肿瘤靶向药物[J].癌症进展,2007,5(2):173-177. 被引量:9
  • 2MANLEY P W, SHIEH W C, SUTTON P A, et al. Preparation of salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl ]-3 - ( 4- ( 3 - pyridinyl ) pyrimidin-2-ylamino ) benzarnide: WO, 2007/015871 [P]. 2007 - 02 - 08. 被引量:1
  • 3MANLEY P W, SHIEH W C, SUTTON P A, et al. Crystalline forms of 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethyl phenyl] -3 - (4- ( 3 - pyridin- yl) pyrimidin-2- ylamino) benzamide: WO, 2007/015870 [P]. 2007 - 02 - 08. 被引量:1
  • 4DAVIES S L, BOLOS J, SERRADELL N, et al. Nilotinib[J ]. Drugs Fur, 2007, 32(1) : 17 - 25. 被引量:1
  • 5Novartis Pharmaceuticals Inc. Tasigna (nilotinib) prescribing information[EB/OL]. [ 2007 - 10 - 29 ]. http://www. pharma. us. novartis, com/product/pl/pdf/tasigna. pdf. 被引量:1
  • 6Deininger MW. Nilotinib [J]. Clin Cancer Res, 2008, 14(13): 4027-4031. (CA2009, 150: 15552) 被引量:1
  • 7Jabbour E, Cortes J, Kantarjian H, et al. Drug evaluation: Nilotinib---a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond [J]. Drugs, 2007, 10(7) : 468-479. (CA 2008, 149: 69381) 被引量:1
  • 8Huang WS, Shakespeare WC. An efficient synthesis of nilotinib (AMNI07) [J]. Synthesis, 2007, (14) : 2121-2124. (CA 2007, 147: 448724) 被引量:1
  • 9Werner B, Pascal F, Sandra J, et al. Inhibitors of protein kinases: US, 2008188451 [P]. 2008-08-07; WO, 2004005281 [P]. 2003-07-04. (CA 2004, 140: 77161) 被引量:1
  • 10Shieh WC, McKenna J. Process for the synthesis of 5- (methyl- 1H-imidazol- 1 -yl) -3- (trifluoromethyl) bene- zeneamine: US, 2008188656 [P]. 2008-08-07; WO, 2006135641 [P]. 2006-12-21. (CA2007, 146: 81883) 被引量:1

共引文献8

同被引文献44

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部